Actelion’s first-quarter earnings up 25%, beating forecasts
Switzerland-based Actelion (SIX: ATLN) saw its shares rise over 5% to 119.50 Swiss francs in early trading this morning, as the company posted first-quarter 2015 financials that beat analysts’ expectations.
Actelion, Europe’s largest biotech firm, reported net earnings for the quarter of 159 million francs ($166 million), up 25% but 29% higher at constant exchange rates. Revenues rose 10% to 515 million francs (up 12% at CER). A Reuters poll had forecast product sales of 477 million francs and net income of 132 million francs.
Product sales performance
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze